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Abstract Because of an important burden of disease, obesity
is a major public health challenge in the twenty-first century.
Where medico-psychological management has shown its
limitations, bariatric surgery is now acknowledged as the most
efficient therapy potentially offered to severely obese patients.
Among other options, Roux-en-Y gastric bypass (RYGBP) is
the most frequently performed procedure. The objective of this
review is to systematically evaluate the effect of the Roux-
(alimentary) limb length on postoperative weight loss after
RYGBP in severely obese patients.MEDLINE, EMBASE and
the Cochrane Central Register of Controlled Trials (CEN-
TRAL) were searched using terms related to Roux-limb,
gastric bypass and obesity. To be included, studies had to be
either randomized controlled trials, quasi-randomized con-
trolled trials or prospective cohort studies comparing a shorter
to a longer Roux-limb. Studies were critically appraised with
regard to methodological components. Eight studies were
reviewed. Variations in methodology, operation design and
outcome assessment among studies caused considerable
clinical heterogeneity, preventing us from performing a meta-
analysis. The overall quality was questionable, owing to lack
of rigor in methodological components reporting. Results were
heterogeneous, but we identified a trend supporting that the
construction of a longer Roux-limb is more efficient in super
obese patients. This review suggests that the tailoring of a
longer Roux-limb might only be efficient in super obese
patients. The overall limited quality of the included studies
prompts to call for improvement in trial design in surgery.
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Introduction
Obesity is a global public health challenge and there is
worldwide concern about this health condition. During the
past two decades, bariatric surgery has been repeatedly
shown to be beneficial to severely obese patients, by safely
achieving outcomes such as weight loss and co-morbidity
control [1–4]. Accordingly, bariatric surgery is now recog-
nized as the main component of morbid obesity treatment
and can be dichotomized into two main kinds of procedure:
restrictive and malabsorptive [5]. Roux-en-Y gastric bypass
(RYGBP), the most commonly performed procedure, com-
bines both aspects, as it consists of the creation of a small
gastric pouch combined with a gastrointestinal bypass [6–8].
Even though most of its effects are believed to be caused by
restriction, the bypassing of a large proportion of the
stomach, the duodenum and various lengths of the jejunum
is also likely to contribute to weight loss [9, 10]. Initially
designed for morbidly obese patients, RYGBP has been
shown to be less efficient in super obese populations [11–
13]. This finding encouraged surgeons aiming at more
satisfying results to imagine variations of RYGBP. Among
the various components of the RYGBP that can be modified,
lengthening the portion of the intestine within which
absorption is limited—because of a lack of interaction of
food with bile and pancreatic enzymes—appears as an
appealing opportunity to improve weight loss profile.
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Objectives
The objective of this review is to assess the evidence
regarding the efficacy of tailoring a longer as compared to a
shorter Roux-limb for improving weight loss profile in
morbidly obese (BMI≥35 kg/m2) patients undergoing
RYGBP surgery. More in-depth questions to be addressed
in this review are:
& Does the construction of a longer Roux-limb improve
long-term weight loss results?
& Is Roux-limb length a determinant of postoperative
weight loss in both morbidly and super obese (cf.
definitions below) patients?
& Does the Roux-limb length have an effect on obesity
related co-morbidities, such as type 2 diabetes (T2DM),
dyslipidaemia, hypertension (HTN), sleep apnea syndrome
(SAS) and gastroesophageal reflux disease (GERD)?
& Is there a relationship between the risk of nutritional
deficiencies after RYGBP and Roux-limb length?
Methods
Types of Studies
Studies included were randomized controlled trials (RCTs)
comparing long vs. short Roux-limb in severely obese patients
treated with RYGBP, regardless of the surgical technique
(laparoscopy vs. open surgery). Anticipating the paucity of
available literature, it was decided to include quasi-
randomized controlled trials and prospective cohort studies
as well. To be included, studies had to have at least a 12-month
follow-up. Studies were included irrespective of publication
status. The assessed literature was written in either English,
French, Italian or Spanish. Exclusion criteria were: any kind
of study design that included retrospectively collected data;
studies that did not compare different intervention groups (one
long Roux-limb vs. one short Roux-limb): for instance case
series, studies assessing Roux-limb length variation in other
setting than RYGBP (e.g. biliopancreatic diversion with or
without duodenal switch) or secondary analyses based on
previously published reports.
Patients
All the patients included in this review were adults
(≥18 years old) who met the criteria for surgical treatment.
With respect to obesity, included participants had to fall in
one of the following categories:
& Morbid obesity, defined as a BMI≥40 kg/m2 (or ≥35
with clinically relevant obesity related co-morbidities/
high health risk) or an absolute body weight ≥45 kg
higher than ideal body weight, depending on the studies
considered
& Super obesity, defined as a BMI≥50 kg/m2 or an
absolute body weight ≥90 kg higher than ideal body
weight, depending on the studies considered
& Super-super obesity, defined as a BMI≥60 kg/m2
Types of Outcomes and Their Measurements
Outcomes of interests were of three types:
& Weight loss indicators, such as mean weight loss (MWL)
(kilogram), mean absolute weight (MAW) (kilogram),
excess weight loss (%EWL), success rate (defined as the
percentage of patients achieving a %EWL≥50%), mean
absolute BMI (MAB) (kilogram per square metre) and
mean BMI loss (or change) (kilogram per square metre).
& Co-morbidity indicators such as, respectively:
T2DM control (fasting glucose level <100 mg/dl,
random glucose level <200 mg/dl, glycated haemoglo-
bin <6%, achievement of treatment interruption);
T2DM improvement (no insulin necessary or decreased
drug dosage of diabetes medications) [14, 15]
Dyslipidaemia control (total cholesterol <200 mg/dl,
LDL-cholesterol <100, 130 and 160 mg/dl with respec-
tively existing coronary artery disease, two or more risk
factors and fewer than two risk factors for coronary artery
disease, HDL-cholesterol <35 mg/dl, fasting triglycerides
<20 mg/dl, achievement of treatment interruption); dysli-
pidaemia improvement (lipid profile normalized by
medication) [15]
HTN control (systolic and/or diastolic blood pressure
<140 and 90 mmHg, respectively, with diet or diuretic
medications only); HTN improvement (blood pressure
normalized by medication) [15]
& Nutritional status and/or deficiencies, assessed by
repeated blood level measurement of nutrients such as
Haemoglobin; albumin; vitamins A, B1, B6, B12 and D;
folates; electrolytes (iron, calcium, magnesium, zinc)
Search Strategy
Firstly, we searched the following electronic databases:
MEDLINE (1966 onwards), EMBASE (1980 onwards) and
The Cochrane Central Register of Controlled Trials
(Clinical Trials; CENTRAL). The search terms used for
MEDLINE were the following1: 1 morbid obesity.mp. OR
Obesity, Morbid/ OR Obesity/ OR (superobese or super-
1 “/” defining MeSH term and “mp.” defining a random keyword term
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obese or super obese or superobesity or super-obesity or
super obesity).mp. 2 Gastric Bypass/ OR anastomosis,
roux-en-y/ OR gastroenterostomy/ 3 long limb.mp. OR
short limb.mp. OR limb length.mp OR (limb lengthening or
limb extending).mp OR distal.mp. Then, we combined
these terms in a query formulated as “1 AND 2 AND 3”.
We also used additional resources to identify further
relevant trials: the manually scanned reference lists of all
papers retrieved from electronic search; the hand-search of
journals with specialized interest in the concerned subject
such as Obesity (2000 onwards), International Journal of
Obesity (1997 onwards), Obesity Surgery (1991 onwards),
Surgery for Obesity and Related Diseases (2005 onwards)
and Obesity Research & Clinical Practice (2007 onwards).
Finally, we attempted to find relevant studies not yet/or not
published through the web site www.clinicaltrial.gov and
the grey literature.
Results
Search
The electronic search yielded a result of 172 articles (125 in
MEDLINE, 47 in EMBASE, CENTRAL providing only
articles already retrieved from the two former sources).
Hand scanning the reference lists of the relevant articles,
searching articles in specialized journals and the grey
literature provided one potentially includable article. After
careful reading of the titles and abstracts, we decided to
exclude 155 articles, based on either retrieving the same
paper from several sources or irrelevant subject. Out of the
18 remaining articles, 9 were excluded: 7 for inappropriate
design (retrospective case series) [16–22], 1 was a narrative
review [23] and 1 used a fixed Roux-limb length,
evaluating common limb length as the primary exposure
variable [24]. Details of the inclusion/exclusion process can
be found in Fig. 1.
Characteristics of Studies
Nine articles met the inclusion criteria [25–33]. Out of
these, five were RCTs [25, 27, 29, 30, 33] and four were
prospective cohort studies [26, 28, 31, 32]. See ESM
Table A1 for details of the included studies. After thorough
reading of the papers, it appeared that two studies [26, 28]
had overlapping author lists and had been conducted in the
same medical centre. We contacted the author, who
confirmed that the study populations of the two papers
were derived from the same cohort. Therefore, we further
excluded one article [26]. We had the same impression
regarding two other RCTs [27, 29]. Again, we contacted the
author, who excluded overlapping of the two study
populations; thus, we kept both papers.
Original searching electronic databases 
(MEDLINE,  EMBASE and CENTRAL): 
 172 articles identified 
Additional sources (reference hand-scanning, 
specialized journals searching, www.clinicaltrial.gov, 
grey literature): 1 relevant article 
155 articles excluded based 
on 
 either title or abstract 
 (including same article 
retrieved from multiple 
databases) 
18 potentially relevant 
articles  9 articles excluded:  
1 review, 
7 retrospective case-series,  
1 study assessing common limb 
length, not Roux-limb length, as the 
primary independent variable 
8 articles included:  
5 randomized controlled trials, 
3 prospective cohort studies 
1 article further excluded because of data 
overlapping with  
another publication 
Fig. 1 Flow chart of the
inclusion/exclusion process
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In addition to our critical appraisal, the quality of the
studies was graded according to the five-point Jadad score
[34] (see Table 2).
Six studies were performed in the USA [25, 27–31], one
in Brazil [33] and one in Switzerland [32]. Publication
dates ranged from 1992 [25] to 2008 [28, 31, 33].
Number of Patients
Overall, these 8 studies comprised a total of 699 patients
(391 in RCTs).
No study reported having conducted an a priori power
analysis. The study by Inabnet [30] was the only one stating
the a priori sample size goal (n=100), although it failed to
provide the rationale of it.
Patients
Four studies mentioned adhering to NIH Consensus
Development Conference Panel on gastrointestinal surgery
for severe obesity [27, 29, 31, 33]. Three studies included
only super obese patients [25, 28, 33]. One study focused
on patients with BMI<50 [30]. Otherwise, both morbid and
super obese patients were eligible. Demographic character-
istics are presented in the ESM Table A1. Only the study by
Ciovica showed some uneven distribution of baseline
characteristics among intervention arms [28]. Muller com-
pared two subsequent groups of patients treated differently
and randomly matched each of the two groups for sex, age
and baseline BMI. Paired analysis was conducted, compar-
ing patients drawn from each of the two groups [32].
Data of all the included studies were prospectively
collected.
Surgical Procedures
The operative protocols were thoroughly described in all the
included studies. With regard to the Roux-limb lengths, there
was clinical heterogeneity (or variability) in intervention
design: Brolin compared limbs of 75 to 150 cm. Choban
and Flancbaum stratified patients according to their initial
BMI, obtaining four groups: among patients with BMI<50,
they compared lengths of 75 to 150 cm, and among those with
BMI>50, they compared 150 to 250 cm [27, 29]. Two studies
tailored limbs of either 100 or 150 cm [28, 30]. Pinheiro
allocated patients to Roux-limb length of either 150 or
250 cm [33]. Muller opted for an original design, comparing
a proximal gastric bypass procedure with a distal one [32]. In
the former procedure, a Roux-limb of 150 cm was created,
whereas in the latter the distance from the Roux-en-Y
anastomosis to the ileocaecal valve (the common limb) was
fixed at 100–150 cm. Lee evaluated the relationship between
weight loss and varying Roux-limb lengths in a continuum:
for patients with BMIs≤40, Roux-limb were 100 cm; for
every unit of BMI over 40, the surgeon added 5 cm extra
limb length. For example, a patient with BMI of 42 was
given a Roux-limb length of 110 cm. The maximum length
was limited to 150 cm [31].
The technique used for limb length measurement was
described in five papers. Three used a pre-cut measurement
tape [27, 30, 31], one measured 10 cm steps using a marked
laparoscopic forceps with the bowel held taut but not
stretched [32] and one reported only measuring the distance
between gastrojejunostomy and jejunojuejunostomy hold-
ing the bowel on a stretch, omitting to describe the
measurement scale [25].
Outcomes and Effect of Intervention
It is worthwhile to notice that some authors chose to report
results at specific time points and not regularly throughout
follow-up; for instance, Inabnet [30] and Ciovica [28]
provided MWL at 12 months post-surgery only. On the
other hand, Muller [32] reported results of a 4-year follow-up
analysis. See Table 1 for outcome reporting.
Weight Loss Profile
MWL and MAB were reported in (or could be deduced from
the results of) four [25, 27, 29, 30] and six studies [25, 27,
28, 30–32], respectively. The five RCTs and the study by
Ciovica [28] described EWL%. Success rate was discussed
by Brolin (at 24 months only) and Choban [25, 27].
In his 1992 landmark paper, Brolin compared short
(Roux-limb 75 cm, biliopancreatic limb 15 cm) vs. long
limbs (Roux-limb 150 cm, biliopancreatic limb 30 cm) in
45 super obese patients [25]. The MWL was greater among
the long limb group throughout the whole follow-up, with a
statistically significant difference observed at 24 and
36 months. MAB followed the same trend, with statistical
significance at 24 months only.
After stratified randomization, Choban showed that
success rate was significantly higher at 18 months in super
obese patients that had been allocated to the long limb
group [27]. This association was not observed among
morbidly obese patients. All the other assessed outcomes
failed to show statistical significance.
Flancbaum performed an RCT assessing weight loss
profile in four groups of patients [29], using the same
stratified randomization scheme as Choban [27]. Flancbaum
did not detect any statistical evidence for difference in MWL
or EWL% at 12-months of follow-up in either morbidly
obese or super obese patients [29].
The study by Inabnet assessed the effect of Roux-limb
length in 48 patients with a BMI≤50 kg/m2. The Roux-
limb was either 100 or 150 cm. This study failed to show
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evidence to support the intervention in a non-super obese
population; in fact, there was a non-statistically significant
difference inMAW, EWL% andMAB between short and long
limb groups, respectively, at 3, 6, 12 and 24 months [30].
Pinheiro did not find any significant difference in EWL
% between the two study groups [33].
Ciovica provided the reader with several positive results
supporting the intervention in a super obese population.
The following indicators were improved at 12 months post-
surgery in the intervention group [28]:
& MWL (55.3 (95% CI 52.2–58.5) vs. 68.5 (61.3–73.9))
(p<0.01)
& MAB in kg/m2 (40 (95% CI 39–41) vs. 36 (34–38))
(p<0.01)
& Mean BMI change in kg/m2 (21 (95% CI 20–22) vs. 25
(23–27)) (p=0.03)
& EWL% (53% (95%CI 50–56) vs. 64% (58–69)) (p=0.02)
Muller observed a BMI decrease from 45.9 to 31.7 kg/m2
in the proximal group and from 45.8 to 33.1 kg/m2 in the
distal group. This represents a 3% difference in percentage
BMI between the two groups. These results did not reach
statistical significance [32].
Finally, Lee demonstrated that there was a linear
relationship between Roux-limb length and both MWL
and mean BMI change (p=0.0025 and 0.0011, respectively)
[31]. These regression models show relatively flat slopes
(0.075 and 0.19), meaning that each additional centimetre
in Roux-limb length would lead to a slight increase in either
BMI change or absolute weight loss.
Co-morbidities
Improvement of co-morbidities was investigated in the
studies by Pinheiro, Brolin and Muller [25, 32, 33]. T2DM
improvement or control, improvement in lipid disorders and
HTN were assessed in the three papers. As opposed to that,
SAS and GERD were variably taken into account. Pinheiro
showed that during the first 12 weeks following interven-
tion, T2DM control was achieved in 93% vs. 58% of
patients allocated to long and short limb, respectively (p<
0.05). Dyslipidaemia was improved in 70% of patients
within the long limb group, whereas only 57% of the short
limb group showed improvement (p<0.05). There was no
statistical evidence for improvement in HTN. Both groups
were declared to be cured of GERD symptoms and SAS
[33]. Brolin provided details of the incidence of pre- and
postoperative obesity co-morbidities, but the study was
underpowered to detect any statistically significant differ-
ence among intervention groups [25]. Muller showed that
T2DM, dyslipidaemia and HTN were reduced in all
intervention groups, although no statistical significance for
the difference between groups was found [32].
Nutritional Outcomes
Six studies took nutritional outcomes into account [25, 27,
29–31, 33]. Inabnet obtained the results of 56% and 52%
patients in the short and long limb groups, respectively, and
there were no formal comparative results reported in the
manuscript or tables [30]. Flancbaum found no association
Table 1 Outcomes investigated in the included studies
Study design Outcomes
Postoperative weight loss Surgical
complications/
mortality/
nutritional
complications
T2DM–
dyslipidaemia/
hypertension/sleep
apnea/GERD
Mean
absolute
weight
(kg)
Mean
weight
loss
(kg)
Mean
absolute
BMI
(kg/m2)
Mean
BMI
change
(kg/m2)
Excess
weight
loss
(%)
Success
rate (%)
Brolin 1992 [25] RCT − + + + + + +/+/+ +/+/+/−
Flancbaum 1998
[29]
RCT − + − − + − −/−/+ −/−/−/−
Choban 2002 [27] RCT − + − + + + +/+/+ −/−/−/−
Inabnet 2005 [30] RCT + − + − + − +/+/+ −/−/−/−
Lee 2006 [31] Prospective
cohort study
− + − + − − −/−/+ −/−/−/−
Pinheiro 2008 [33] RCT − − − − + − −/+/+ +/+/+/+
Ciovica 2008 [28] Prospective
cohort study
− + + + + − −/−/− −/−/−/−
Muller 2008 [32] Prospective
cohort study
− − + + − − +/+/− +/+/−/−
"+" means that the item was reported in—or imputable from—the study under consideration; "−" means that the item was not reported in—or
imputable from—the study under consideration
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between Roux-limb length and measured resting energy
expenditure [29].
No study found significant difference regarding nutritional
outcomes between groups. See ESM Table A1.
Risk of Bias in the Included Studies
Of the five RCTs, none reported either the method used for
generation of allocation sequence or whether the actual
allocation sequences were concealed from study practi-
tioners. No RCT declared to have analysed the data
according to the intention-to-treat principle.
The study by Inabnet was the only one to report blinding
of the surgical team, operating room staff, ancillary staff,
consultants and patients to group allocation [30].
Discussion
Out of eight studies, four provided some evidence support-
ing the construction of a long Roux-limb at improving
postoperative weight loss profile. The results of these
studies suggest that the benefit is strictly restricted to super
obese patients. These results are consistent with several
retrospective analyses that were not included in this paper
[19–21]. The apparent lack of efficiency of constructing a
long Roux-limb in the morbidly non-super obese patients
could be interpreted as either a lack of statistical power (or
type II error) of the individual studies or as bias introduced
by some unexplored variables. For example, intestinal
adaptation, a pattern of morphostructural and functional
changes compensating for the loss of digestive and
absorptive capacity after small bowel resection and mal-
absorptive surgery [35, 36], might have shifted the results
toward the null hypothesis, limiting the impact of a long
gastrointestinal bypass and acting as a negative confounder.
Because a mixture of study designs (RCTs and cohort
studies), extra care would have been necessary if a meta-
analysis had been carried out. Furthermore, the eight
included articles showed clinical heterogeneity, limiting
the relevance of performing a meta-analysis. Heterogeneity
was found in three main aspects. First, definition of “short”
and “long” limb varied, as did the techniques used to
measure limb length. Accordingly, some studies considered
a given Roux-limb length as a short one, and others as a
long one [25, 33], potentially introducing misclassification.
Secondly, different kinds of patients were included, some
studies focusing on particular sub-populations such as super
obese patients [25, 28, 33] or diabetic [33], and others
allowing for more permissive inclusion criteria [27, 29, 31,
32]. Thirdly, follow-up duration and time points chosen for
hypothesis testing were varied. Besides Brolin’s, Pinheiro’s
and Muller’s studies [25, 32, 33], there was limited follow-
up and short follow-up durations might not be adequate for
studies dealing with weight loss profile after RYGBP. There
are two main reasons for this: first, it is likely that a
substantial proportion of the weight loss occurring after
RYGBP—especially during the first postoperative year—is
actually attributable to the restrictive part of the procedure,
in other words, the tailoring of a small gastric pouch [31,
37, 38]. Secondly, gastric bypass and more generally
bariatric surgery procedures are not punctual interventions
that resolve a specific pathological condition; they are
interventions that must be put into the context of a more
holistic approach, including medical, surgical and behav-
ioural aspects. Therefore, short follow-up studies might
draw insufficient conclusions, considering the realistic and
complex conditions entailed in long-term management of
severe obesity. Although not formally included in this
review, the retrospective analysis of Christou and col-
leagues skilfully addressed time-to-intervention issues by
providing data of more than 10 years of follow-up [39].
Patients in this series were either treated with a long
(100 cm) or a short (40 cm) Roux-limb. There was
evidence supporting that after a nadir occurring at 2.2
postoperative years on average, MAB starts to rise again.
Table 2 Methodology of the included studies
Study design Adequate allocation
sequence
Allocation
concealment
Blinding Jadad score
Brolin 1992 [25] RCT ? No No 2
Flancbaum 1998 [29] RCT ? No No 1
Choban 2002 [27] RCT ? No No 1
Inabnet 2005 [30] RCT ? No Yes 3
Lee 2006 [31] Prospective cohort study Not applicable Not applicable Not applicable Not applicable
Pinheiro 2008 [33] RCT ? No No 1
Ciovica 2008 [28] Prospective cohort study Not applicable Not applicable Not applicable Not applicable
Muller 2008 [32] Prospective cohort study Not applicable Not applicable Not applicable Not applicable
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Super obese patients lost weight significantly more quickly
and subsequently gained weight more quickly as well.
Overall, Christou and colleagues found no evidence
suggesting that a long Roux-limb provided more satisfying
results than a short one.
Finally, other methodological weaknesses such as lack of
allocation sequence description and concealment status
among RCTs undermined the overall validity of the results
reported (see Table 2).
Conclusions
This review revealed that the body of literature comparing
long to short Roux-limb in RYGBP was poor in quantity
and of questionable quality, owing to a lack of rigour in
reporting important methodological components. The large
clinical variability in both intervention design and outcome
reporting epitomized the weak consensus among bariatric
surgery centres. The heterogeneity in results was notable
and is, in our opinion, attributable to both systematic (bias)
and random errors.
The results collected here suggest that the construction
of a long Roux-limb might be efficacious at improving
postoperative weight loss in super obese (BMI>50 kg/m2)
patients only. Moreover, it does not seem that an increased
limb length jeopardizes the vitamin and mineral absorption
more than a standard RYGBP.
Finally, this paper is an opportunity for us to call
surgeons with research interest for an improvement in the
rigour of their trial design, in order to gain in validity and
interpretability. Such an effort should particularly make the
results of surgical trials more amenable to meta-analyses,
which, thanks to their increased statistical power, guide
clinical practice more than any other research design.
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